Equities
Health CareMedical Equipment and Services
  • Price (EUR)14.98
  • Today's Change0.28 / 1.90%
  • Shares traded164.01k
  • 1 Year change-38.05%
  • Beta--
Data delayed at least 15 minutes, as of Feb 13 2026 16:35 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

SCHOTT Pharma AG & Co. KGaA is a Germany-based company. The Company is primarily engaged in designing advanced drug containment solutions and drug delivery systems for the pharmaceutical and biotech industries. The Company’s portfolio ranges from syringes and cartridges to vials and ampoules, all made using Type I Borosilicate Glass and high-grade pharmaceutical polymer.

  • Revenue in EUR (TTM)996.56m
  • Net income in EUR150.74m
  • Incorporated2022
  • Employees4.81k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gerresheimer AG2.25bn23.35m687.00m13.54k29.420.49012.460.30530.6760.67665.1540.590.54553.737.85185,328.900.63413.300.87164.6826.8930.041.165.840.52142.080.602241.292.287.90-5.526.3217.58-49.35
Paul Hartmann AG2.43bn81.51m782.36m10.09k9.540.66354.060.322422.9522.95682.93330.051.161.975.54240,745.704.124.215.455.7959.5657.303.563.351.1114.110.246537.952.321.95281.5813.2310.082.71
Eckert & Ziegler SE304.47m40.62m950.20m1.11k23.144.0416.643.120.64650.63284.853.700.65273.486.10280,619.308.858.6211.0610.4347.2548.5313.5514.182.3768.350.16632.1220.2210.6333.4012.7018.843.30
Draegerwerk AG & Co KGaA3.42bn120.88m1.49bn16.68k10.850.86895.550.43446.456.45182.3580.561.132.515.01206,009.004.003.725.945.5945.3544.543.533.491.037.960.163716.12-0.07783.9212.6537.910.468359.64
SCHOTT Pharma AG & Co KgaA996.56m150.74m2.26bn4.81k14.942.439.442.261.001.006.636.180.64143.953.98207,141.309.7411.8613.6116.8733.6834.6515.1815.681.17--0.082410.953.0411.04-2.1613.5811.15--
Carl Zeiss Meditec AG2.20bn120.62m2.40bn5.78k19.51----1.091.371.3725.58--------381,084.40--8.00--9.7852.1956.025.5311.56--7.38--33.147.8210.78-20.992.9011.231.92
Ottobock SE & Co KgaA1.64bn57.90m3.67bn--63.4416.0519.282.240.90480.904825.673.58----------------52.42--3.42--0.64583.180.8358--7.33---38.37------
Data as of Feb 13 2026. Currency figures normalised to SCHOTT Pharma AG & Co KgaA's reporting currency: Euro EUR

Institutional shareholders

12.83%Per cent of shares held by top holders
HolderShares% Held
T. Rowe Price International Ltd.as of 29 Oct 20257.55m5.01%
Capital Research & Management Co. (World Investors)as of 24 Sep 20254.37m2.90%
Union Investment Privatfonds GmbHas of 30 Sep 20252.46m1.63%
The Vanguard Group, Inc.as of 04 Feb 20261.33m0.88%
T. Rowe Price Hong Kong Ltd.as of 31 Dec 20251.14m0.76%
Norges Bank Investment Managementas of 30 Jun 2025655.66k0.44%
Grandeur Peak Global Advisors LLCas of 31 Oct 2025611.18k0.41%
Montanaro Asset Management Ltd.as of 31 Dec 2025510.00k0.34%
BlackRock Fund Advisorsas of 06 Feb 2026404.30k0.27%
Lupus alpha Asset Management AGas of 30 Jun 2025298.70k0.20%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.